NIMH Pages about Medications
- Clinical Tests Begin on Medication to Correct Fragile X Defect
- November 02, 2009 • Press Release
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder’s neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.
- Significant Weight Gain, Metabolic Changes Associated with Antipsychotic Use in Children
- October 27, 2009 • Science Update
Many children and adolescents who receive antipsychotic medications gain a significant amount of weight and experience metabolic changes, according to NIMH-funded research published October 28, 2009, in the Journal of the American Medical Association.
- Combination Treatment for Psychotic Depression Holds Promise
- August 07, 2009 • Science Update
A combination of an atypical antipsychotic medication and an antidepressant known as a selective serotonin reuptake inhibitor (SSRI) may be more effective in treating psychotic depression than an atypical antipsychotic alone, according to results from an NIMH-funded clinical study.
- Questions Raised About Stimulants and Sudden Death
- June 15, 2009 • Science Update
A study examining stimulant use among children and adolescents found an association between stimulants and sudden unexplained death in youth with no evidence of pre-existing heart disease. The finding draws attention to the potential risks of stimulant medication, according to the study’s authors; an accompanying editorial notes that the rarity of sudden unexplained death and the lack of long-term data on the effectiveness of these medications for reducing other health risks make a full benefit/risk assessment difficult.
- Citalopram No Better Than Placebo Treatment for Children with Autism Spectrum Disorders
- June 01, 2009 • Press Release
Citalopram, a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to researchers funded by the National Institute of Mental Health (NIMH) and other NIH institutes. The study was published in the June 2009 issue of Archives of General Psychiatry.
More Science News…
- The 13th NIMH Biennial Research Conference on the Economics of Mental Health
- September 25, 2006 – September 26, 2006
Bethesda, Maryland
In September 2006, the NIMH Division of Services and Intervention Research (DSIR) sponsored a national research conference on mental health economics.
- NIMH/National Business Group on Health Roundtable on Medication Management in Employer-Based Behavioral Health Systems
- July 01, 2006
Washington, DC
The Services Research and Clinical Epidemiology Branch of the NIMH Division of Services and Intervention Research held this one-day meeting to identify relevant research findings for employers and to discuss new opportunities to bridge the gap between research and practice.
- NCDEU Meeting
- June 01, 2006
Boca Raton, Florida
Named after the original NIMH New Clinical Drug Evaluation Unit clinical trials program, the NCDEU meeting has grown and evolved over the years to include a broad range of academic and industry investigators, practitioners, and NIMH and FDA staff.
More Meeting Summaries…
